Loading patent…
AssigneeSolvay Pharmaceuticals GmbH
InventorsKlaus Witte, Dieter Ziegler, Matthias Straub, Paulus Koopman
Estimating the term…
A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).
A pharmaceutical composition comprising pharmacologically effective quantities of each of
A method of treating or ameliorating a cardiovascular disorder or disease in a mammal comprising administering to a subject in need thereof an effective amount of a combination of at least one neutral endopeptidase inhibitor, at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor.
A method of treating or ameliorating a metabolic disorder or disease in a mammal comprising administering to a subject in need thereof an effective amount of a combination of at least one neutral endopeptidase inhibitor, at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor.
A kit comprising:
Dependencies are inferred from the claim text.